Landmark Petition to Reschedule Psilocybin filed with DEA

Date: February 3, 2022

Landmark Petition to Reschedule Psilocybin filed with DEA

View PDF

 Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with  ongoing international research on the effectiveness of psilocybin in mental health care

Statement:

Following issuance of the Ninth Circuit’s opinion in AIMS v DEA on Monday (1/31), finding lack of jurisdiction to review the DEA’s refusal to allow access to psilocybin pursuant to duly enacted Right to Try laws, Petitioners have filed a Petition for Rescheduling of Psilocybin from schedule I to schedule II. The Petition offers DEA a way to create a pathway so that terminally ill patients can access to psilocybin.

In a letter to the DEA sent on January 18, bipartisan Congressional members encouraged DEA to use its power to create a pathway to access psilocybin, shown to be remarkably effective in relieving anxiety and depression in patients with advanced illness.  Given that the interests of terminally ill patients are at stake, where the advance of illness makes time short, there is an urgency for DEA’s action on the Petition. Congressional interest in the DEA’s response to this Petition will likely be keen.

On today’s Psychoactive Podcast Matt Johnson, the first researcher to be appointed to an endowed chair in psychedelic studies, the Susan Hill Ward Professor in Psychedelics and Consciousness at Johns Hopkins University, says leaving psilocybin on schedule I is “absolutely absurd.”

https://www.iheart.com/podcast/1119-psychoactive-84544756/episode/30-matt-johnson-on-pioneering-92422650/

(at minute: 19:52)

Latest Blog Posts

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

LJ STANDISH AND DAVID JAMES Dr. Standish and her team can help improve brain function, improve memory and slow cognitive decline in Alzheimer’s disease.  Please make an appointment to start.  Call 206-420-1321.  Scientific Rationale A protocol incorporating low-dose lithium orotate, Lion’s Mane mushroom extract, NADH, transcranial magnetic stimulation (TMS), and blood sugar regulation counseling is scientifically rational for treating cognitive decline based on mechanistic, preclinical, and emerging human studies. Low-Dose Lithium Orotate (5 mg/day) Recent brain tissue studies link low brain lithium to the onset and progression of Alzheimer’s disease, with deficiency accelerating synaptic loss and cognitive decline. Low-dose lithium orotate has ...

Read More
One Doctor’s Campaign to Let the Dying Take Psychedelics

One Doctor’s Campaign to Let the Dying Take Psychedelics

Psilocybin mushrooms on a dehydrator tray. Photographer: Jason Connolly/AFP/Getty Images By Charles Gorrivan September 3, 2025 at 3:00 AM PDT Corrected September 3, 2025 at 9:04 AM PDT Hi, it’s Charles in New York. When Brave New World author Aldous Huxley was on his deathbed in 1963, his wife injected him with two doses of LSD, the powerful psychedelic, as he slipped away. Was Huxley on to something? More on that in a moment, but first … Today’s must-reads RFK Jr. set new priorities for the CDC after firing its director. A big Danish pension fund bets that Novo Nordisk ...

Read More
Call Us Text Us
Skip to content